UK’s CMA Drops Part Of Prochlorperazine Probe
But Will Continue To Investigate Alleged Anti-Competitive Overarching Agreement
Executive Summary
The UK’s Competition and Markets Authority has closed “on administrative priorities grounds” its investigation into individual agreements between Alliance Pharmaceuticals, Focus Pharmaceuticals, Medreich and Lexon UK over the supply of prochlorperazine. However, an allegedly anti-competitive “overarching agreement” will continue to be investigated.
You may also be interested in...
UK’s CMA Puts Investigations On Hold
Two investigations by the UK’s Competition and Markets Authority over behaviour around prochlorperazine and nitrofurantoin have been put on hold due to the coronavirus pandemic.
UK's Competition Watchdog Targets Four Firms Over Seven-Fold Prochlorperazine Price Hike
The UK CMA alleges that four companies were involved in a non-compete agreement that resulted in a 700% increase in the cost to the NHS of a generic medicine for nausea and dizziness.
Aspen Expects Growth Following Sandoz And Viatris Deals
Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: